Overcoming drug resistance in hormone-and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination

Simple item page
dc.contributor.authorCengiz E.
dc.contributor.authorKaraca B.
dc.contributor.authorKucukzeybek Y.
dc.contributor.authorGorumlu G.
dc.contributor.authorGul M.K.
dc.contributor.authorErten C.
dc.contributor.authorAtmaca H.
dc.contributor.authorUzunoglu S.
dc.contributor.authorKarabulut B.
dc.contributor.authorSanli U.A.
dc.contributor.authorUslu R.
dc.date.accessioned2024-07-22T08:21:06Z
dc.date.available2024-07-22T08:21:06Z
dc.date.issued2010
dc.description.abstractDrug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose-and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array® (SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated C3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers. © Springer Science+Business Media B.V. 2009.
dc.identifier.DOI-ID10.1007/s11033-009-9501-y
dc.identifier.issn15734978
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18465
dc.language.isoEnglish
dc.subjectApoptosis
dc.subjectCell Line, Tumor
dc.subjectDNA, Complementary
dc.subjectDose-Response Relationship, Drug
dc.subjectDrug Resistance, Neoplasm
dc.subjectDrug Therapy, Combination
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectGene Expression Profiling
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectGossypol
dc.subjectHumans
dc.subjectMale
dc.subjectProstatic Neoplasms
dc.subjectTaxoids
dc.subjectTime Factors
dc.subjectdocetaxel
dc.subjectgossypol
dc.subjectcomplementary DNA
dc.subjectdocetaxel
dc.subjectgossypol
dc.subjecttaxoid
dc.subjectapoptosis
dc.subjectarticle
dc.subjectcancer cell culture
dc.subjectcarcinogenesis
dc.subjectcell cycle regulation
dc.subjectcell metabolism
dc.subjectcell viability
dc.subjectconcentration response
dc.subjectcontrolled study
dc.subjectcytotoxicity
dc.subjectDNA repair
dc.subjectdose time effect relation
dc.subjectdown regulation
dc.subjectdrug potentiation
dc.subjectgene expression profiling
dc.subjecthuman
dc.subjecthuman cell
dc.subjectmale
dc.subjectpolymerase chain reaction
dc.subjectprostate cancer
dc.subjectapoptosis
dc.subjectdose response
dc.subjectdrug combination
dc.subjectdrug effect
dc.subjectdrug resistance
dc.subjectenzyme linked immunosorbent assay
dc.subjectgene expression regulation
dc.subjectgenetics
dc.subjectphysiology
dc.subjectprostate tumor
dc.subjecttime
dc.subjecttumor cell line
dc.titleOvercoming drug resistance in hormone-and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination
dc.typeArticle

Files

Collections

Scopus Koleksiyonu